Roche

Q1 2018 results

Basel, 26 April 2018 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website www.roche.com All mentioned trademarks are legally protected. 3 Group

Severin Schwan Chief Executive Officer Q1 2018: Strong sales growth in both divisions

2018 2017 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 10.7 10.2 5 7

Diagnostics Division 2.9 2.8 5 5

Roche Group 13.6 12.9 5 6

CER=Constant Exchange Rates 5 Q1 2018: Sales growth for the seventh consecutive year

10%

8% 8% 7% 7% 6% 6% 6% 6% 6% 6% 6% 6% 6% 6% 5% 5% 5% 5% 4% 4% 4% 4% 4% 4% 4% 3% 3% 2% 2%

0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 12 12 12 12 13 13 13 13 14 14 14 14 15 15 15 15 16 16 16 16 17 17 17 17 18

All growth rates at Constant Exchange Rates (CER) 6 Q1 2018: Strong sales growth in US and International

CHFbn 7 +14% 6 +8%

5

4 +6% -5% Diagnostics 3 +15% Pharma +9% -1%

2 0% +5% -7% 1 -8% 0% 0 Japan International Europe US

All growth rates at Constant Exchange Rates (CER) 7 Roche significantly advancing patient care, BTD’s reflecting the quality of our research

Phase duration (years)

No = 7.5

Fast track = 5.8

Accelerated review = 3.8

Breakthrough therapy = 3.6

8 2018: New products with annualized sales of >CHF 8bn* ~80% of growth driven by new products

* Venclexta sales are booked by partner AbbVie. 9 Replace and extend the business Through continuously improving standard of care

Entering new Replace existing businesses Achievements Q1 2018 franchises

Gazyva, Perjeta: Launched in eBC in US Venclexta, MabThera MS: , Ocrevus Gazyva: Launched in FL in US/EU Sub Cut Hemlibra: Launched in inh. patients in US/EU; BTD in non-inh. Perjeta, Herceptin Kadcyla, Tecentriq: IMpower150 with OS benefit Sub Cut Hemophilia: Venclexta: Launched in 17p del; Filed in CLL R/R Hemlibra Tecentriq, Avastin baloxavir: Filing initiated in US entrectinib entrectinib: Acquisition of Ignyta completed VA2, Lucentis port delivery CNS: VA2: Strong Ph II data in DME SMA, Autism, Tamiflu baloxavir (Cap Endo) Huntington’s

VA2=anti-VEGF/anti-angiopoietin-2 bispecific antibody; MS=multiple sclerosis; SMA=spinal muscular atrophy; eBC=early breast cancer; FL=follicular lymphoma; BTD=Breakthrough 10 Therapy Designation; CLL R/R=relapsed/refractory (R/R) chronic lymphocytic leukemia; DME=diabetic macular edema Record number of NMEs at pivotal stage Q1 entrants: Anti-VEGF/Ang2 biMAb, entrectinib, baloxavir marboxil

Oncology Ophthalmology Neuroscience Immunology Infectious Disease

NME=new molecular entities; For details on the indications and line extensions please consult the pipeline appendix. Cap Endonuclease inhibitor (baloxavir marboxil) 11 2018 outlook raised From “stable to low single digit” to “low single digit”

Group sales growth1 • Low-single digit

• Broadly in line with sales, excl. US tax reform benefit Core EPS growth1 • High-single digit, incl. US tax reform benefit

Dividend outlook • Further increase dividend in Swiss francs

1 Sales growth at Constant Exchange Rates (CER) 12 Pharmaceuticals Division

Daniel O’Day CEO Roche Pharmaceuticals

13 Q1 2018 performance

Innovation

Outlook

14 Q1 2018: Pharma sales Accelerated growth in US due to new products

2018 2017 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 10,672 10,177 5 7 United States 5,516 5,070 9 15 Europe 2,287 2,273 1 -7 Japan 851 856 -1 0 International 2,018 1,978 2 5

CER=Constant Exchange Rates 15 Q1 2018: New products with strong momentum, out growing biosimilar onset

Absolute values and growth rates at Constant Exchange Rates (CER) 16 Q1 2018: Oncology sales stable

YoY CER growth Perjeta • Perjeta: Strong growth in all regions; US momentum due to early APHINITY approval HER2 Herceptin +6% • Kadcyla: Growth driven by International Kadcyla • EU: Decline largely due to price cut in France Avastin -2% • US/EU: 1L lung cancer shares stable after CIT entry Gazyva/Gazyvaro

Hematology MabThera/Rituxan • US/EU: Good initial uptake of Gazyva in 1L FL in the early launch countries (Oncology) -7%

Tarceva -32% • Increased competition

• EU: Launch in lung (2/3L) and bladder (2L and 1L cisplatin ineligible) ongoing Tecentriq +29% • US: 2L lung cancer and 1L cisplatin ineligible bladder shares stable

• US: 1L new patient market share of >50% achieved following 1L approval in Q4 Alecensa +81% • EU: Strong 1L launch in key markets Cotellic Cotellic + -6% • EU: Increasing competition from CIT Zelboraf

CHFbn 0 1 2 3

Q1 2018 Oncology sales: CHF 6.4bn (CER growth 0%); All growth rates at Constant Exchange Rates (CER); CIT=cancer immunotherapy; FL=follicular lymphoma 17 Her2 franchise: Growth driven by Perjeta

CHFm YoY CER growth 3,000 +6% +6% Her2 franchise Q1 2018 2,500 +9% +23% • Perjeta US (+18%): Accelerated growth driven by eBC following approval in the adjuvant setting (APHINITY) 2,000 • Perjeta in eBC on NCCN, St. Gallen, and AGO (Germany) 1,500 guidelines

Outlook 2018 1,000 • US: Continued Perjeta uptake in eBC 500 • EU: Approval in adjuvant BC (APHINITY) • EU: Market entry of Herceptin biosimilars 0 Q1 15 Q1 16 Q1 17 Q1 18 Herceptin Perjeta Kadcyla

CER=Constant Exchange Rates; eBC=early breast cancer; NCCN=National Comprehensive Cancer Network; AGO=Arbeitsgemeinschaft Gynäkologische Onkologie 18 Hematology: Entering the rejuvenation phase

CHFm YoY CER growth Hematology Q1 2018 2,000 CD20 franchise • MabThera (onc) US (+2%): Stable volumes in all indications +4% +5% +3% • MabThera (onc) EU (-43%): Biosimilar roll-out ongoing 1,500 -7% • Gazyva (+27%): Growth driven by 1L FL early launches Venclexta* 1,000 • Venclexta sales reached USD 59m (+179%) with ~40% patient share reached in R/R CLL with 17p deletion

500 Outlook 2018 • US: first biosimilar entry in H2 expected • US/EU approval Venclexta + Rituxan in R/R CLL (MURANO) 0 • Ph II data for Polatuzumab vedotin + BR in R/R DLBCL to be Q1 15 Q1 16 Q1 17 Q1 18 shared with health authorities MabThera/Rituxan (Onc) Gazyva/Gazyvaro

CER=Constant Exchange Rates; FL=follicular lymphoma; CLL=chronic lymphoid leukemia; BR=bendamustine+Rituxan; DLBCL=diffuse large B-cell lymphoma; * Venclexta sales are 19 booked by partner AbbVie. Alecensa: US market leadership in 1L ALK+ NSCLC achieved

CHFm YoY CER growth Alecensa Q1 2018 150 • US: New patient share of >50% in first quarter of launch +81% 125 • Launch supported by FMI`s NGS-based companion diagnostic (FoundationOne CDx) and approval of the 100 Ventana companion diagnostic

75 +124% • EU: Strong launch in key markets

50 +161% Outlook 2018 25 • Continued 1L momentum

0 • Updated mPFS data from Ph III study (ALEX) comparing Q1 15 Q1 16 Q1 17 Q1 18 Alecensa vs crizotinib to be presented at ASCO US Europe International Japan • Ph III adjuvant study (ALINA) initiated

CER=Constant Exchange Rates; FMI=Foundation Medicine; NGS=next generation sequencing 20 Immunology: Annualized sales of around CHF 8bn

CHFm YoY CER growth Immunology Q1 2018 +4% 2,000 +11% Esbriet (+13%) +16% 1,600 • Penetration in mild to moderate patient segment increasing +20% Xolair (+7%) 1,200 • Growth driven by pediatric asthma, allergic asthma and CIU 800 Actemra (+13%) • Launch in giant cell arteritis ongoing 400 • Auto-injector approved in the EU and Australia

0 Q1 15 Q1 16 Q1 17 Q1 18 Outlook 2018 MabThera/Rituxan (RA) Actemra IV Actemra SC Xolair • Strong growth expected with the exception of MabThera CellCept Pulmozyme Esbriet Other

CER=Constant Exchange Rates; CIU=chronic idiopathic urticaria 21 Ocrevus: Strong EU launch; ~7% US market share after 3 quarters

CHFm 600 Ocrevus Q1 2018 • Strong launches in EU and International 500 • US growing due to increasing number of returning patients 400 and new patients • RMS: 30% treatment naive/previously discontinued vs. 70% 300 switches from all other approved medications

200 Outlook 2018 100 • Continued launches in EU and International

0 • Further increasing US market share with earlier use Q2 17 Q3 17 Q4 17 Q1 18

US Europe International

RMS=relapsing forms of multiple sclerosis 22 2018: New products with annualized sales of >CHF 8bn* ~80% of growth driven by new products

* Venclexta sales are booked by partner AbbVie. 23 Q1 2018 performance

Innovation

Outlook

24 CIT 1L lung cancer program reading out in H1 2018

IMpower1331 (Tecentriq+cb+etoposide) IMpower150 (PFS) PFS/OS (Tecentriq+cb/pac+/-Avastin) PFS/OS (H1 2018) (OS)

With liver IMpower130 metastases (Tecentriq+cb+nab-pac) PFS/OS IMpower131 (Tecentriq+cb+pac/nab-pac) IMpower132 PFS/OS (Tecentriq+cp/cb+pem) PFS/OS (PFS)

= Roche with potential first chemo combo

March 26: IMpower150 met co-primary OS endpoint at interim analysis March 20: IMpower131 met co-primary PFS endpoint

Source: Datamonitor; incidence rates 7 major markets (US, Japan, France, Germany, Italy, Spain, UK); Note: Outcome studies are event driven, timelines may change; 1IMpower133 in extensive stage SCLC; CIT=cancer immunotherapy; cb=carboplatin; pac=paclitaxel; nab-pac=nab-paclitaxel (Abraxane); cp=cisplatin; pem=pemetrexed 25 Tecentriq in 1L non-squamous NSCLC IMpower150: A unique opportunity in key subgroups

PDL-1 status (SP142 and SP263) and Teff signatures EGFR/ALK genetic alterations and liver metastases

• Clinically meaningful PFS benefit in ITT and key subgropus (EGFR/ALK+ and patients with liver metastases) • PD(L)1 monotherapy has not shown significant benefit in 2L EGFR/ALK+ patients • Tumors in patients with liver metastases are characterized by immune suppressive tumor environments, and they usually demonstrate poorer outcomes • The observed efficacy in these key subgroups may be due to the addition of Avastin to Tecentriq

Kowanetz M, et al., AACR 2018; ITT=intent-to-treat; WT=wild type; mPFS=median progression free survival; TC=tumor cells; IC=immune cells 26 Hemlibra: BTD for non-inhibitor prophylaxis HAVEN 3 and 4 submitted to WFH

HAVEN 3 and 4 submitted to WFH (Glasgow, May 20-24) Hemlibra designated as Part B drug by CMS

BTD=breakthrough designation; WFH=world federation of hemophilia; CMS=centers for medicare & medicaid services 27 Baloxavir marboxil* in Influenza A & B FDA filing for healthy adults and adolescents planned in 2018

CAP-dependent Phase III (CAPSTONE-1) results for acute uncomplicated influenza endonuclease inhibitor

• Small molecule inhibiting viral • Significant reduction in time to alleviation of symptoms by >24 hrs vs placebo (p<0.0001) RNA replication via a novel and • Time to cessation of viral shedding reduced by 48 hrs vs Tamiflu (p<0.0001) potentially highly selective mode of action leading to reduced transmission rates • One-time dosing due to long half- • Approved in Japan in Feb 2018 life + well tolerated • Ongoing Ph III development program in populations at high risk and pediatrics

Kawaguchi, et al. ESWI 2017; Portsmouth, et al. IDWeek 2017; a 95% CI of median time could not be obtained by Brookmeyer and Crowley method (1982); b Not determined; *Co-development with Shionogi; Roche holds worldwide license excluding Japan and Taiwan 28 Acquisition of Flatiron in Q1 Leading player driving personalized patient care in oncology

Strong network in Oncology • Leading EMR system and analytics solutions used by ~15% of US oncologists and covering ~15% of active patients

Leading real world data base • Research-quality EMR data base covers 10m patients, over 2m of them active • 90% of large Pharma companies are working with Flatiron data

While Flatiron will remain independent, acquisition will help to expand our existing partnership and provide required resources to accelerate key strategic projects in the field of personalized healthcare

29 ASCO 2018: Highlights in various cancer types*

Lung Biomarker development • Tecentriq + cb/pac +/- Avastin: Ph III OS (IMpower150) in 1L • Tecentriq: Ph II interim analysis (B-F1RST) to support blood TMB non-squamous NSCLC as predictive biomarker • Tecentriq + cb + pac/nab-pac: Ph III PFS (IMpower131) in 1L • Tecentriq: Tissue TMB as predictive biomarker in NSCLC, mUC squamous NSCLC and melanoma • Alecensa: Ph III update (ALEX) in 1L ALK+ NSCLC Hematology Hepatocellular carcinoma • Venclexta + Rituxan: Ph III (MURANO) MRD analysis in R/R • Tecentriq + Avastin: Ph Ib expansion (GO30140) in HCC CLL • Venclexta + dec/aza: Ph Ib (NCT02203773) in 1L AML Breast • Venclexta + car + dex: Ph II (NCT02899052) in R/R MM • Ipatasertib: Ph II (LOTUS) in 1L TNBC

*Planned submissions (to be confirmed); Outcome studies are event driven, timelines may change; cb=carboplatin; pac=paclitaxel; nab-pac=nab-paclitaxel (Abraxane); TMB= tumor mutational burden; aza=azacitidine; dec=decitabine; car=carfilzomib; dex=dexamethasone; Alecensa in collaboration with Chugai; Venclexta in collaboration with AbbVie 30 Q1 2018 performance

Innovation

Outlook

31 2018: Key late-stage news flow*

Compound Indication Milestone

Ocrevus RMS / PPMS EU approval Perjeta + Herceptin Adjuvant HER2+ eBC EU approval Tecentriq + cb/pac +/- Avastin 1L non-sq NSCLC US/EU filing Tecentriq + Avastin 1L RCC US/EU filing Regulatory Hemlibra Hemophilia A inhibitors EU approval Hemlibra Hemophilia A non-inhibitors US/EU filing Hemlibra Every 4 weeks dosing inhibitors/non-inhibitors US/EU filing baloxavir marboxil Influenza A and B US filing Venclexta + Rituxan R/R CLL US/EU approval Tecentriq + chemo 1L lung program Ph III IMpower130/132/133 Tecentriq + chemo 1L lung program Ph III IMpower131 Phase III readouts Tecentriq + nab-pac 1L TNBC Ph III IMpassion130 Tecentriq + Cotellic 2/3L CRC Ph III IMblaze370 / COTEZO Actemra Systemic sclerosis Ph III focuSSced

* Outcome studies are event-driven: timelines may change 32 Diagnostics Division

Roland Diggelmann CEO Roche Diagnostics

33 Q1 2018: Diagnostics Division sales Good growth in all business units

2018 2017 Change in % CHFm CHFm CHF CER Diagnostics Division 2,911 2,765 5 5 Centralised and Point of Care Solutions 1,716 1,641 5 4 Diabetes Care 478 447 7 5 Molecular Diagnostics 468 441 6 6 Tissue Diagnostics 249 236 6 7

CER=Constant Exchange Rates 34 Underlying growth of Molecular Diagnostics excluding sequencing business: +7% Q1 2018: Diagnostics regional sales Growth driven by Asia Pacific and North America

Japan North America -8% +7% EMEA1 3% of divisional sales 26% of divisional sales +2% 42% of divisional sales

Asia Pacific Latin America +10% +1% 23% of divisional sales 6% of divisional sales

+9% growth in E7 countries2

1 Europe, Middle East and Africa; 2 Brazil, China, India, Mexico, Russia, South Korea, Turkey All growth rates at Constant Exchange Rates 35 Q1 2018: Diagnostics Division highlights Growth driven by Immunodiagnostics

YoY CER growth

Centralised • Immunodiagnostics (+5%); clinical and Point of +4% Care chemistry (+3%) Solutions

Diabetes • US blood glucose measurement business +5% Care (+24%)

Molecular • Virology (+5%), HIV (+20%); HPV (+5%); +6% Diagnostics1 cobas® Liat® (+262%)

Tissue EMEA +7% • Advanced staining portfolio (+8%); primary Diagnostics North America staining (+20%) RoW

CHFbn 0.0 0.5 1.0 1.5 2.0

1 Underlying growth of Molecular Diagnostics excluding sequencing business: +7% 36 CER=Constant Exchange Rates; EMEA=Europe, Middle East and Africa 5,000 installations of cobas® 8000 modular analyzer series Performing 15m tests/day

+30%

5,188 4,878

No of installations 3,747

2,945

2,222

1,526

969 470 157 15

2009 2010 2011 2012 2013 2014 2015 2016 2017 YTD March 2018

37 Strong Flu season driving cobas® Liat® System sales Pediatric and emergency room focus segments

Growing number of placements worldwide

cobas® Liat® cobas® Liat® EU ~220 Analyzer assay tube US ~1500

APAC ~15

• Easy to use with less than one minute hands on time • Lab quality performance in 20 minutes or less Chile ~8

Menu of assays available

CE US

Suitable for testing in a variety of settings cobas® Influenza A/B  

cobas® Strep A  

cobas® Influenza A/B & RSV  

cobas® Cdiff 

38 Launch of cobas® Plasma Separation Card For testing and monitoring of HIV patients in resource limited settings

• No refrigeration needed for patient plasma samples during transport to the lab • Only card that meets the WHO sensitivity requirement for determining HIV treatment • Compatible with HIV-1 viral load testing on the cobas® 6800/8800 and cobas® AmpliPrep/TaqMan systems

39 Launch* of VENTANA DP 200 slide scanner for digital pathology Reliable, high-speed scanning of histology slides, with excellent image quality

• Unique no-touch slide processing reduces slide handling errors • Application of the International Color Consortium profile matching what is observed under a microscope • Digital Imaging and Communications in Medicine (DICOM) Standard compatible • Provides a foundation for a future menu of Roche image analysis algorithms VENTANA DP 200 slide scanner

*CE marked for IVD use; approved in the US for research use only 40 Key launches 2018

Area Product Market

Central Laboratory cobas pro integrated solution – Serum Work Area solution for medium throughput to lower high throughout labs CE

Specialty Testing cobas m 511 – World's first fully digital morphology analyzer and cell counter US

Instruments/ Workflow CCM connectivity to cobas c513 – Connection of cobas c 513 to CCM Automation System for high volume HbA1c testing WW Devices Tissue Dx BenchMark ULTRA Plus – New and differentiated Advanced Staining System CE

Digital Pathology VENTANA DP200 – Reliable low-volume scanner with superior image quality CE

Diabetes Care Solo Patch Pump – Small and tubeless insulin delivery device operated through a remote control which includes a blood glucose meter CE Endocrinology IGFBP3 – Completion of the existing growth hormone menu of hGH and IGF-1 CE

Infectious Diseases Zika IgG – Highly specific immunoassay for the in vitro qualitative detection of IgG antibodies to Zika virus in human serum and plasma CE Tests/ cobas CT/NG – Highest throughput CT/NG test on the market with workflow efficiency benefits US Assays Microbiology cobas 6800/8800 MTB/MAI – High volume solution for MTB/MAI testing; efficient approach to disease management (mixed testing) for infectious disease CE Virology Plasma Separation Card – Card-like sample collection device; separates plasma from whole blood; for use with CAP/CTM HIV- 1 & cobas HIV-1 (6800/8800) CE Sequencing AVENIO FFPET RUO oncology kits – 3 separate tissue based assay kits for solid tumors WW

Software Decision Support NAVIFY Tumor Board v 1.x – EMR integration WW

41 Finance

Alan Hippe Chief Financial Officer

42 Q1 2018: Highlights

Sales • Strong Group sales growth, particularly in the US (+14%) and International (+6%) • Strong growth in both divisions, Pharmaceuticals (+7%); Diagnostics (+5%)

M&A • Ignyta deal closed (USD 1.7bn) • Flatiron Health deal closed (USD 1.9bn)

Currency impact on sales • Overall slightly negative - negative USD development only partially offset by EUR

All growth rates at Constant Exchange Rates (CER) 43 Q1 2018: Group sales Sales increase driven by US, Diagnostics Division and International

+15% -7% +5% 0% +5% +6% +5%

Pharma Division +7% +129 -180 +757 -166 +97 +4

+821 +641

United States Europe Intl. Japan Diagnostics Group Fx1 Group Division CHF

Absolute values and growth rates at Constant Exchange Rates (CER) 44 ¹ average Full Year 2017 to average Q1 2018 Fx Exchange rate impact on sales growth Negative impact from USD, partially offset by EUR

+0.3p +0.1p 0.0p -0.1p +1.6p -0.5p -2.8p

CER CHF sales sales growth growth YTD Mar +6.4% YTD Mar 2018 +5.0% 2018 vs. vs. YTD Mar YTD Mar 2017 2017

CER EUR Other As-Pac Other JPY Lat-Am USD CHF Europe

CER = Constant Exchange Rates (avg full year 2017) 45 Low currency impact expected in 2018

CHF / USD

Average -6% -4% -3% -3% YTD 2017 1.00 0.99 0.98 0.98 Assuming the 31 March 2018 exchange rates remain stable 0.95 0.95 0.95 0.95 until end of 2018, Assumed average YTD 2018 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 2018 impact is expected to be (%p): 0.96 0.93 0.95 Monthly avg fx rates 2018 Fx rates at 31 Mar 2018 Q1 HY Sep YTD FY J F M A M J J A S O N D

CHF / EUR Sales -1 0 0 0

+9% +9% +7% +6% Core operating 0 -1 1.16 1.17 1.17 1.17 profit

1.11 Core EPS 0 -1 1.09 1.07 1.08

1.17 1.15 1.17 1.18 1.18 1.18 1.18 1.18 1.18 1.18 1.18 1.18

J F M A M J J A S O N D

46 2018 outlook raised From “stable to low single digit” to “low single digit”

Group sales growth1 • Low-single digit

• Broadly in line with sales, excl. US tax reform benefit Core EPS growth1 • High-single digit, incl. US tax reform benefit

Dividend outlook • Further increase dividend in Swiss francs

1 Sales growth at Constant Exchange Rates (CER) 47 Pipeline summary

Marketed products additional indications

Global Development late-stage trials pRED (Roche Pharma Research & Early Development) gRED ( Research & Early Development)

Roche Group Q1 2018 results

Diagnostics

Foreign exchange rate information 48 Changes to the development pipeline Q1 2018 update

New to phase I New to phase II New to phase III New to registration

2 NMEs: 1 NME: 2 AIs: 1 AI: RG6148 NME –HER2+ BC RG6268 entrectinib – NSCLC ROS1+ RG7446 Tecentriq + Avastin – 1L HCC RG105 MabThera/Rituxan – pemphigus RG6173 NME – asthma RG7446 Tecentriq – SCCHN adj vulgaris 1 AI: 1 NME from Chugai: RG6268 entrectinib – NTRK1 pan tumor CHU NME - endometriosis

3 AIs: RG7421 Cotellic + Tecentriq – RCC, UC, H&N cancer RG7440 ipatasertib + Tecentriq + taxane - TNBC RG7601 Venclexta + Cotellic ± Tecentriq - MM

Removed from phase I Removed from phase II Removed from phase III Removed from registration

1 NME: 1 NME: 1 NME following EU approval: RG7945 NME - glaucoma RG3637 lebrikizumab ± Esbriet – IPF RG6013 Hemlibra – hemophilia A FVIII inh

1 AI following US approval: RG3645 Lucentis 0.3mg PFS – DME/DR

49 Status as of April 26, 2018 Roche Group development pipeline

Phase I (45 NMEs + 26 AIs) RG6264 Perjeta + Herceptin FDC SC HER2+ BC T + Cotellic solid tumors RG6069 anti-fibrotic agent fibrosis RG6026 CD20 TCB heme tumors T + ipi/IFN solid tumors RG6107 C5 inh MAb PNH RG6058 tiragolumab (TIGIT) ± T solid tumors T + Tarceva/Alecensa NSCLC RG6151 - asthma RG6109 - AML T + anti-CD20 combos heme tumors RG6173 - asthma RG6114 mPI3K alpha inh HR+ BC T ± lenalidomide ± MM RG6174 - inflammatory diseases RG6146 BET inh combos solid + heme tumors RG7446 T + K/HP HER2+ BC RG7835 IgG-IL2 FP autoimmune diseases RG6148 - HER2+ BC T + HMA MDS RG7880 IL-22Fc inflammatory diseases RG6160 - multiple myeloma T + radium 223 mCRPC RG7990 - asthma RG6171 SERD (3) ER+ (HER2neg) mBC T + guadecitabine AML RG6004 HBV LNA HBV RG6180 personalized cancer vaccine ± T oncology T + rucaparib ovarian ca RG6080 nacubactam bact. infections RG6185 pan-RAF inh + Cotellic solid tumors T + Gazyva/tazemetostat r/r DLBCL + FL RG7854 TLR7 agonist (3) HBV emactuzumab + T solid tumors RG7461 FAP IL2v FP combos solid tumors RG7861 anti-S. aureus TAC infectious diseases RG7155 emactuzumab + selicrelumab solid tumors Venclexta + Cotellic/idasanutlin AML RG7907 HBV Capsid (2) HBV RG7159 anti-CD20 combos heme tumors RG7601 Venclexta ± azacitadine r/r MDS RG7992 FGFR1/KLB MAb metabolic diseases RG7386 FAP-DR5 biMAb solid tumors Venclexta + Cotellic ± T MM RG6000 - ALS Cotellic + Zelboraf + T melanoma RG7741 ChK1 inh solid tumors RG6029 Nav1.7 inh (2) pain RG7421 Cotellic + T 2L BRAF WT mM RG7802 CEA TCB ± T solid tumors RG6042 ASO Huntington’s Cotellic + T RCC, UC, H&N ca RG7813 CEA IL2v FP* + T solid tumors RG7816 GABA Aa5 PAM autism RG7440 ipatasertib + taxane + T TNBC RG7828 CD20 TDB ± T heme tumors RG7906 - psychiatric disorders Tecentriq solid tumors selicrelumab (CD40) + T solid tumors RG6147 - geographic atrophy RG7876 Tecentriq NMIBC selicrelumab + solid tumors PTH1 recep. ago hypoparathyroidism RG7446 T-based Morpheus platform solid tumors RG7882 MUC16 ADC ovarian ca CHU - hyperphosphatemia T + Avastin + Cotellic 2/3L CRC Raf/MEK dual inh solid tumors - endometriosis CHU T ± Avastin ± chemo HCC, GC, PaC glypican-3/CD3 biMAb solid tumors

New Molecular Entity (NME) CardioMetabolism RG-No Roche/Genentech *INN: cergutuzumab amunaleukin Additional Indication (AI) Neuroscience CHU Chugai managed **out-licensed to Galderma and Maruho AD Oncology Ophthalmology PRO Proximagen managed *** Ph2 pivotal Immunology Other NOV Novimmune managed T=Tecentriq Infectious Diseases RG1569 Branded as RoActemra (EU) TCB=T cell bispecific TDB=T cell dependent bispecific 50 Status as of April 26, 2018 Roche Group development pipeline

Phase II (19 NMEs + 10 AIs) Phase III (9 NMEs + 36 AIs) entrectinib NSCLC ROS1+ Kadcyla HER2+ BC adj RG7446/RG7853 Tecentriq or Alecensa 1L NSCLC Dx+ RG6268 RG3502 entrectinib NTRK1 pan tumor Kadcyla + Perjeta HER2+ BC adj Venclexta + Gazyva 1L CLL RG7388 idasanutlin polycythemia vera Hemlibra hemophilia A w/o FVIII inh Venclexta + bortezomib MM RG6013 RG7601 RG7421 Cotellic + T ± taxane TNBC Hemlibra Q4W hemophilia A Venclexta + azacitidine 1L AML RG7440 ipatasertib TNBC neoadj RG7388 idasanutlin + chemo AML Venclexta + LDAC 1L AML RG7596 polatuzumab vedotin r/r DLBCL + FL ipatasertib + abiratorone 1L CRPC RG7604 taselisib + fulvestrant ER+(HER2-neg) mBC Venclexta + Rituxan DLBCL RG7440 ipatasertib + chemo 1L TNBC/HR+ BC RG7601 Venclexta + Rituxan r/r FL RG105 MabThera pemphigus vulgaris Cotellic+Zelboraf+T 1L BRAFm melanoma RG1569 Actemra systemic sclerosis Venclexta + azacitadine 1L MDS RG7421 RG7604 taselisib + letrozole (HER2-neg) BC neoadj Cotellic + T 1L BRAF WT melanoma RG3648 Xolair nasal polyps RG7686 codrituzumab HCC RG7596 polatuzumab vedotin 1L DLBCL etrolizumab ulcerative colitis RG7413 RG6125 Cadherin-11 MAb RA Tecentriq NSCLC adj etrolizumab Crohn’s RG6149 ST2 MAb asthma Tecentriq MIBC adj RG6152 baloxavir marboxil influenza RG7159 lupus Tecentriq Dx+ 1L sq + non-sq SCLC RG1450 gantenerumab Alzheimer’s RG7625 Cat-S antag autoimmune diseases Tecentriq RCC adj RG6168 satralizumab NMO RG7845 fenebrutinib (BTK inh) RA, lupus, CSU T + nab-paclitaxel 1L non-sq NSCLC RG6206 anti-myostatin adnectin DMD CHU nemolizumab** pruritus in dialysis patients T + chemo+ Avastin 1L ovarian cancer RG7412 crenezumab Alzheimer’s PRO VAP-1 inh inflammatory disease T + chemo + Avastin 1L non-sq NSCLC NOV TLR4 MAb autoimmune diseases T + pemetrexed 1L non-sq NSCLC CHU URAT1 inh gout T + nab-paclitaxel 1L sq NSCLC Registration (5 AIs) RG1662 basmisanil CIAS RG7446 T ± chemo SCCHN adj RG435 Avastin1 ovarian FL RG1678 bitopertin beta thalassemia T + paclitaxel 1L TNBC RG1273 Perjeta + Herceptin2 HER2+ BC adj RG6083 olesoxime SMA T + nab-paclitaxel 1L TNBC RG7601 Venclexta + Rituxan r/r CLL RG6100 Tau MAb Alzheimer’s T + nab-paclitaxel TNBC neoadj RG1569 Actemra auto injector3 RA RG7314 balovaptan autism T + Avastin RCC RG105 MabThera/Rituxan pemphigus vulgaris RG7916 SMN2 splicer(2)*** SMA T + Avastin 1L HCC 1 2 3 RG7935 α-synuclein MAb Parkinson's T + Cotellic 3L CRC US only, Approved in US, Approved in EU RG3645 ranibizumab PDS wAMD See previous page for legend T ± chemo 1L mUC RG7716 VEGF-ANG2 biMAb wAMD, DME T + chemo 1L extensive stage SCLC T + enzalutamide CRPC 51 Status as of April 26, 2018 NME submissions and their additional indications Projects currently in phase II and III

New Molecular Entity (NME) CardioMetabolism Additional Indication (AI) Neuroscience Oncology Ophthalmology Immunology Other Infectious Diseases

✓ Indicates submission to health authorities has occurred Unless stated otherwise submissions are planned to occur in US and EU

gantenerumab RG1450 Alzheimer‘s

basmisanil VEGF/ANG2 biMAb RG1662 RG7716 CIAS wAMD/DME

bitopertin Cadherin-11 MAb RG1678 RG6125 beta thalassemia RA

anti-myostatin adnectin olesoxime ST2 MAb RG6206 RG6083 RG6149 DMD SMA asthma satralizumab SMN2 splicer(2) idasanutlin Tau MAb etrolizumab RG6168 (SA237) RG7916 RG7388 RG6100 RG7413 SMA polycythemia vera Alzheimer’s neuromyelitis optica ulcerative colitis baloxavir marboxil entrectinib ipatasertib+abiratorone ipatasertib balovaptan etrolizumab RG6152 RG6268 RG7440 RG7440 RG7314 RG7413 Influenza NSCLC ROS1+ 1L CRPC TNBC neoadj autism Crohn’s

polatuzumab vedotin entrectinib polatuzumab vedotin polatuzumab vedotin crenezumab Cat S antag RG7596 RG6268 RG7596 RG7596 RG7412 RG7625 r/r DLBCL NTRK1 pantumor r/r FL 1L DLBCL Alzheimer’s autoimmune diseases taselisib+fulvestrant taselisib + letrozole idasanutlin ipatasertib +chemo α-synuclein MAb fenebrutinib RG7604 PIK3CAmut ER+ RG7388 RG7440 RG7604 ER+ (HER2-neg) RG7935 RG7845 Parkinson’s autoimmune diseases (HER2-neg) mBC AML 1L TNBC / HR+ BC BC neoadj 2018 2019 2020 2021 and beyond Status as of April 26, 2018 52 AI submissions for existing products; currently in phase II and III

MabThera ✓ RG105 pemphigus vulgaris New Molecular Entity (NME) CardioMetabolism Actemra RG1569 Additional Indication (AI) Neuroscience systemic sclerosis Oncology Ophthalmology Actemra auto injector (US) RG1569 Immunology Other RA/GCA ✓ Infectious Diseases Hemlibra RG6013 hemophilia A FVIII non-inh ✓ Indicates submission to health authorities has occurred Unless stated otherwise submissions are planned to occur in US and EU Hemlibra RG6013 hemophilia A, Q4W Venclexta + Rituxan (EU) ✓ RG7601 r/r CLL Venclexta + aza/LDAC RG7601 1L AML Tecentriq + Cotellic ranibizumab PDS RG7446 RG3645 3L CRC wAMD Cotellic + Tecentriq Tecentriq+chemo+Avastin RG7421 obinutuzumab RG7446 1L BRAF WT melanoma RG7159 1L non-sq NSCLC lupus nephritis Cotellic + Tecentriq + Tecentriq + nab-paclitaxel Xolair RG7446/ Tecentriq or Alecensa RG7446 RG7421 Zelboraf RG3648 1L sq NSCLC 1L BRAFmut melanoma nasal polyps RG7853 1L NSCLC Dx+ Tecentriq + nab-paclitaxel Tecentriq Kadcyla Tecentriq RG7446 RG7446 RG3502 RG7446 1L non-sq NSCLC 1L non-sq + sq NSCLC (Dx+) HER2+ BC adj. NSCLC adj Tecentriq + pemetrexed Tecentriq + nab-paclitaxel Kadcyla + Perjeta Venclexta + Rituxan Tecentriq RG7446 RG7446 RG3502 RG7601 RG7446 1L non-sq NSCLC TNBC neoadj HER2+ BC adj. r/r FL MIBC adj Tecentriq + chemo Tecentriq + paclitaxel Tecentriq ± chemo Venclexta + Rituxan Tecentriq RG7446 RG7446 RG7446 RG7601 RG7446 1L extens. stage SCLC 1L TNBC 1L mUC DLBCL RCC adj Tecentriq + Avastin Venclexta + Gazyva Tecentriq + enzalutamide Venclexta + aza Tecentriq + Avastin RG7446 RG7601 RG7446 RG7601 RG7446 RCC 1L CLL CRPC 1L MDS 1L HCC Tecentriq + nab-paclitaxel Venclexta + bortezomib Tecentriq+chemo+Avastin Cotellic+Tecentriq±taxane Tecentriq + chemo RG7446 RG7601 RG7446 RG7421 RG7446 TNBC MM 1L ovarian cancer TNBC SCCHN adj

2018 2019 2020 2021 and beyond Status as of April 26, 2018 53 Major granted and pending approvals 2018

US EU Japan-Chugai

Lucentis Ocrevus Hemlibra (emicizumab) Approved RG3645 RG1594 hemophilia A FVIII inh (ped + 0.3 mg PFS DME/DR, March 2018 PPMS & RMS, Jan 2018 RG6013 adults), Hemlibra (emicizumab) March 2018 RG6013 hemophilia A FVIII inh (ped/adults), Tecentriq February 2018 RG7446 2L+ NSCLC, Jan 2018 Actemra auto injector RG1569 RA, March 2018

Tecentriq + other anti-tumor Avastin Perjeta + Herceptin RG435 RG1273 RG7446 drugs Pending Ovarian FL, Filed Aug 2017 HER2+ BC adj, Filed Aug 2017 Approval 1L NSCLC, March 2018 Venclexta + Rituxan Venclexta + Rituxan RG7601 RG7601 r/r CLL, Filed Dec 2017 r/r CLL, Filed Jan 2018

Actemra auto injector MabThera RG1569 RG105 RA/GCA, Filed Jan 2018 pemphigus vulgaris, Filed Feb 2018

Rituxan RG105 pemphigus vulgaris, Filed Dec 2017

New Molecular Entity (NME) CardioMetabolism Additional Indication (AI) Neuroscience Oncology Ophthalmology 54 Immunology Other Status as of April 26, 2018 Infectious Diseases Cancer immunotherapy pipeline overview

Phase I (10 NMEs + 32 AIs) Phase III (22 AIs) RG6026 CD20 TCB hematopoietic tumors AMGN** Tecentriq + talimogene laherp TNBC, CRC Cotellic+Zelboraf+T 1L BRAFm melanoma RG7421 RG6058 tiragolumab (TIGIT) ± T solid tumors Checkmate** Tecentriq + CMP-001 NSCLC Cotellic + T 1L BRAF WT melanoma RG6160 - multiple myeloma BLRX** Tecentriq + BL-8040 AML, solid tumors Tecentriq NSCLC adj RG6180 personalized cancer vaccine ± T oncology CRVS** Tecentriq + CPI-444 solid tumors Tecentriq MIBC adj emactuzumab + T solid tumors EXEL** Tecentriq + cabozantinib solid tumors Tecentriq Dx+ 1L sq + non-sq SCLC RG7155 emactuzumab + selicrezumab solid tumors HALO** Tecentriq + PEGPH20 CCC, GBC Tecentriq RCC adj Cotellic + Zelboraf + T melanoma INO** Tecentriq + INO5401+INO9012 bladder ca T + nab-paclitaxel 1L non-sq NSCLC RG7421 Cotellic + T BRAF WT mM 2L JNJ** Tecentriq ± daratumumab solid tumors T + chemo + Avastin 1L ovarian cancer Cotellic + T RCC, UC, H&N ca KITE** Tecentriq + KTE-C19 r/r DLBCL T + chemo + Avastin 1L non-sq NSCLC RG7440 ipatasertib + taxane + T TNBC T + pemetrexed 1L non-sq NSCLC Tecentriq solid tumors MORPHEUS Platform - Phase Ib/II (5 AIs) T + nab-paclitaxel 1L sq NSCLC Tecentriq NMIBC RG7446 T ± chemo SCCHN adj T-based Morpheus pancreatic cancer T-based Morpheus platform pancreatic ca T + paclitaxel 1L TNBC T-based Morpheus gastric cancer T + Cotellic Avastin 2/3L CRC T + nab-paclitaxel 1L TNBC ± RG7446 T-based Morpheus HR+ BC T Avastin chemo HCC, GC, PaC T + nab-paclitaxel TNBC neoadj ± ± T-based Morpheus NSCLC T + Cotellic solid tumors T + Avastin RCC T-based Morpheus 2L TNBC T + ipi/IFN solid tumors T + Avastin 1L HCC T + Tarceva/Alecensa NSCLC T + Cotellic 3L CRC RG7446 T + anti-CD20 multiple combos lymphoma Phase II (5 AIs) T ± chemo 1L mUC T ± lenalidomide ± daratumumab MM RG7421 Cotellic + T ± taxane TNBC T + chemo 1L extensive stage SCLC T + K/HP HER2+ BC Gradalis** Tecentriq + Vigil ovarian ca T + enzalutamide CRPC T + HMA MDS GTHX** Tecentriq + trilaciclib SCLC RG7446/RG7853 Tecentriq or Alecensa 1L NSCLC Dx+ T + radium 223 mCRPC IMDZ** Tecentriq + NY-ESO-1 soft tissue sarcoma T + guadecitabine AML SNDX** Tecentriq + entinostat TNBC T + rucaparib ovarian ca T + Gazyva/tazemetostat r/r DLBCL + FL RG7461 FAP IL2v FP combos solid tumors RG7601 Venclexta + Cotellic ± T MM ** External collaborations: AMGN – Amgen oncolytic virus; BLRX - BioLine Rx New Molecular Entity (NME) RG-No Roche/Genentech CXCR4 antag; Checkmate - TLR9 agonist; CRVS – Corvus ADORA2A antag; EXEL Additional Indication (AI) *INN: cergutuzumab amunaleukin RG7802 CEA TCB ± T solid tumors – Exelexis’ TKI; Gradalis – EATC therapy; GTHX – G1 Therapeutics CDK4/6; HALO Oncology T=Tecentriq; TCB=T cell bispecific RG7813 CEA IL2v FP* + T solid tumors – Halozyme PEGPH20; IMDZ – Immune Design CMB305; INO - Inovio T cell activating immunotherapy (INO-5401), IL-12 activator (INO-9012); JNJ – Janssen TDB=T cell dependent bispecific RG7828 CD20 TDB ± T solid tumors CD38 MAb; KITE – Kite KTE-C19; SNDX – Syndax HDAC inh selicrelumab (CD40) + T solid tumors RG7876 selicrelumab + vanucizumab solid tumors 55 Status as of April 26, 2018 Doing now what patients need next